AMAALA
AMAALA, the ultra-luxury destination located along Saudi Arabia’s north western coast, took to the seas with Monaco-based OceanoScientific on a two-week scientific expedition. The expedition was in line with AMAALA’s desire to measure and understand the impact of river water pollutants on human and sea life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201104005308/en/
The expedition was undertaken with a two-fold objective to determine the nature and density of the chemical compounds that affect the marine environment. It also placed a wider focus on the impact of chemical contaminants on the ocean and human health, and validates the applicability of the expedition’s sampling method, using a cost-effective research alternative with a zero-carbon emission vessel.
Over the course of two weeks, the crew collected water samples from various points within a triangle of 1,500 nautical miles in the western Mediterranean.
These samples were handed over to the Institut Français de Recherche pour l'Exploitation de la Mer (Ifremer) by the crew and AMAALA Chief Executive Officer Nicholas Naples and Chief Sustainability Officer Brendan Jack at the last port of call in La Seyne-sur-Mer, France. The scientists at the Ifremer, who advised on the scientific aspects of the undertaking, will now quantify and analyse the concentration of metals and elements such as cadmium, lead, nickel and mercury, all of which can alter the composition of the sea and affect the marine food chain.
The expedition and the results unearthed as part of its study will inform AMAALA’s own conservation efforts. The Red Sea and the Mediterranean Sea are neighbouring seas and part of one global ocean system where changes in one, create ripples in the other. With its vibrant coral gardens and rich underwater life, the Red Sea coast at AMAALA has a thriving ecosystem that the destination aims to preserve and nurture. To this end, it has forged partnerships with global marine conservation entities, including the Prince Albert II of Monaco Foundation, the Centre Scientifique de Monaco, and the Oceanographic Institute.
Commenting on the expedition, AMAALA Chief Executive Officer Nicholas Naples, said “We are proud to sponsor the OceanoScientific Expedition – it perfectly aligns with our goal to create a luxury destination that is a global leader in sustainable tourism. Being part of expeditions and studies like this, arms us with the deeper insight and scientific knowledge required to preserve and protect our local ecosystem, especially the Red Sea coral reefs. This expedition also illustrates our vision of creating experiences that brings diverse interests and cultures together.”
Yvan Griboval, circumnavigator explorer and member of the Yacht Club de Monaco, who led the expedition said, “While almost everyone has realised that plastic pollution is an appalling scourge on the ocean, we want to show that chemical contaminants - metallic and organic - that pollute the sea and poison the phytoplankton and plankton at the start of the food chain, are found in our dinner plates at the other end of the chain of life.”
The expedition was conducted on the specially commissioned AMAALA Explorer, a former record-breaking 110-foot racing maxi-catamaran that was converted into a scientific research ship with zero carbon emissions. It functioned as the expedition’s lodging and lab.
HSH Prince Albert II of Monaco on 15 October 2020 was on hand to bid the crew farewell from the marina of the Yacht Club de Monaco. The AMAALA Explorer made port calls in Porto Cervo, Italy; Barcelona, Spain; and La Seyne-sur-Mer, France where water samples were handed over to scientists, before returning to Monaco.
The vessel and expedition were skippered by Yvan Griboval, who worked with a team of scientists specialised in the study of organic contaminants, including an onboard Swedish marine scientist Linn Sekund and AMAALA Director of Sports Marc Archer.
A short documentary film about the expedition, in English and French, will be distributed in 2021, along with scientific results in late 2021 and scientific publication in late 2023.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005308/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
